Clinical Trial Update: ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ctDNA-MRD based adjuvant targeted therapy in EGFR-positive stage I lung adenocarcinoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Lung Adenocarcinoma

Snippet

Sponsor: Peking University People's Hospital | Conditions: Adenocarcinoma of Lung | Phase 1, Phase 2 | Status: UNKNOWN